Recon: House to Vote on Coronavirus Bill; Qiagen Boosts Production of Coronavirus Test Materials

• House slow downs coronavirus bill to consider Trump administration proposals (Reuters) (NYTimes)
• Trump stops Europe flights, China says coronavirus outbreak may end by June (Reuters) (CNN)
• Pence defends coronavirus travel ban, says US cases to rise (Reuters)
• Trump says trade will not be affected by US travel restrictions on Europe (Reuters)
• Trump’s Payroll Tax Cut Would Dwarf the 2008 Bank Bailout (NYTimes)
• White House told federal health agency to classify coronavirus deliberations – sources (Reuters)
• Kymera announces $102 million in new funding to develop treatments for diseases such as blood cancers (STAT) (Endpoints)
• A biotech tests Wall Street's roiled waters and comes away with a $75M IPO haul (Endpoints)
• Lilly, Boehringer's Jardiance nabs speedy FDA review in kidney disease (Fierce) (Press)
• Lilly joins new Medicare scheme to reduce insulin prices (PMLive)
• How Coronavirus Is Affecting The US Pharmaceutical Supply (NPR)

• WHO's Tedros urges world to 'double down' against virus pandemic (Reuters 1, 2)
• Qiagen boosting production of chemical needed to test for coronavirus (Reuters)
• Danish regulator eyes sanctions against trial sponsors that fail to post results (STAT)
• AZ’s comeback drug cediranib stumbles in phase 3 trial  (PMLive) (Endpoints) (Press)
• Teva's Ajovy scores backing from England's cost watchdogs (Fierce)
• Keytruda rejected for NHS use for kidney cancer, will be removed from the Cancer Drugs Fund (Pharmafile)
• UK Research and development investment to rise to record £22bn (Financial Times)
• Key EU notified body meeting goes on, virtually (MedtechDive)

• Human trials testing coronavirus vaccine could begin ‘within a few weeks,’ top US health official says (CNBC) (STAT)
• Here’s the Biggest Thing to Worry About With Coronavirus (NYTimes)
• 'Dr Tedros', the WHO chief leading the fight against the pandemic (Reuters)
• Coronavirus probe at California nursing home slowed by shortage of test kits (Reuters)
• California bans mass gatherings to slow spread of coronavirus (Reuters)
• Many private labs want to do coronavirus tests. But they're still facing obstacles and delays. (NBC)
• UK scientists not recommending U.S.-style travel ban: PM's spokesman (Reuters)
• Confirmed Dutch coronavirus infections rise 22% to 614: health authorities (Reuters)
• Italy toughens coronavirus lockdown after death toll soars (Reuters)
• Three Britons have coronavirus on cruise on Cambodia's Mekong (Reuters)
• Spain's coronavirus outbreak death toll rises to 84 from vs 47 on Wednesday (Reuters)
• Iran asks IMF for $5 billion emergency funding to fight coronavirus (Reuters)
• Death toll in Iran from coronavirus reaches 429: health official (Reuters)
• Number of coronavirus deaths in Britain rises to eight (Reuters)
• Ireland reports first coronavirus death, nine more cases (Reuters)
• South Korea tries to contain smaller outbreaks as new coronavirus cases slow (Reuters)
• France's coronavirus death toll close to 50, new restrictions imposed (Reuters)
• Cuba confirms first coronavirus cases, urges citizens to make own masks (Reuters)
• Guyana confirms first case of coronavirus in woman who returned from US (Reuters)
• Germany reports more than 2,000 coronavirus cases: Johns Hopkins University (Reuters)
• Bolivia coronavirus patient turned away from hospitals; election rallies suspended (Reuters)
• Egypt's confirmed coronavirus cases increase to 67 (Reuters)
• Austria reports first coronavirus death, a 69-year-old who visited Italy (Reuters)
• Costa Rica reports 22 coronavirus cases, nearly double prior tally (Reuters)
• As the coronavirus pandemic continues to rattle the world, biopharma braces for a few new shocks to the system (Endpoints)
• House Oversight committee continues hearing on coronavirus preparedness and response (CNBC)
• Congress shuts down Capitol to the public, White House cancels tours amid coronavirus pandemic (CNBC)
• ECB surprises markets by not cutting rates, but announces stimulus to fight coronavirus impact (CNBC)
• Second US senator closes Washington office amid coronavirus outbreak (Reuters)
• First US hospital chain to treat coronavirus considers treating patients in ‘tents outside’ (CNBC)
• Senators Warren and Murray Urge NIH and FDA to Incorporate the Needs of Pregnant People and Other Underrepresented Populations as Companies Develop Vaccines and Therapeutics for COVID-19 (Warren)
• Coronavirus Test From GenMark Diagnostics Submitted to FDA for Emergency Use Authorization (GenomeWeb)
• Should I Quarantine Because of Coronavirus? It Depends on Who You Ask. (ProPublica)
• Coronavirus on the high seas: Why the U.S. can't touch cruise lines (Politico  )

• How Big Pharma Grew Addicted to Big Profits (NYTimes)
• $1.3 billion per drug? (Nature)
• Priority review vouchers miss the policy mark (Nature)
• Interchangeable Insulins — New Pathways for Safe, Effective, Affordable Diabetes Therapy (NEJM)
• Newer anti-HIV drugs safest, most effective during pregnancy (NIH)
• New drugs are costly and unmet need is growing (The Economist)
• Pharmacogenomics can show what your body makes of a drug (The Economist)
• Microbial signatures in the blood could offer new avenue for liquid biopsies to detect cancer (STAT)
• A one-time biotech unicorn gets slaughtered as lead program is scrapped, highlighting lingering trouble (Endpoints)
• CureVac founder back at the helm; Merck extends immunomodulatory drug discovery program with Sutro (Endpoints)
• After a year of big advances, AstraZeneca CEO Pascal Soriot takes home a major-league pay package (Endpoints)
• How Gilead's blood cancer med Zydelig might also address triple-negative breast cancer (Fierce)
• Vir’s George Scangos teams up with his former colleagues at Biogen to press fast-forward on antibody programs for coronavirus (Endpoints)
• Was it something he said? Biotech CEO who met Trump this month exits without a word (Fierce)
• Harbour BioMed nets $75M in Series B+ as first global trial gets underway (Endpoints)
• Flagship merges two startups to build a $220M Repertoire of T cell tech, therapies (Endpoints)
• Stanford stem cell pioneer nets $194M from Gilead-Forty Seven buyout (Endpoints)
• Back to the drawing board for triple-negative breast cancer targets, researchers propose new combo approach (Endpoints)

• FDA Clears First Clinical Study for a Polymicrobial Phage Library-Based Treatment for Antibiotic-Resistant Infections (Press)
• New Clinical Study Data for Gilead’s Investigational HIV-1 Capsid Inhibitor GS-6207 Presented at CROI 2020 (Press)
• Tenax Therapeutics Completes Enrollment in Phase 2 Pulmonary Hypertension Trial (Press)
• PharmaCyte Biotech Addresses Submission of IND and Recent FDA-Required Testing (Press)
• Virometix Announces Initiation of Phase 1 Clinical Trial With Its V-306 Vaccine Candidate (Press)

• Patient Engagement Forum Postponed (MDIC)
• FDA issues Class I recall for Medtronic's HeartWare HVAD after patient death (MedtechDive)
• ANVISA will implement new rules for medical device modifications in Brazil (Emergo)
• OSSIO Receives FDA 510(k) Clearance for OSSIOfiber® Hammertoe Fixation System (Press)
• Proov gets FDA nod for its at-home ovulation testing kit (mobihealthnews)

• Hospitals turn to big tech companies to store and analyze their data — leaving patients in the dark on privacy protections (STAT) (NYTimes)
• The FTC’s Teami Case: “All [the FTC] really wanna see is the money.” (FDA Law Blog)
• A Couple of Things (Drug & Device Law)
• District Court of Delaware Construes “Following Fermentation” in Genentech v. Amgen Trastuzumab and Bevacizumab Cases (Big Molecule Watch)
• 21 Related Teva Price-Fixing Suits Consolidated (Law360-$)
• Taro Escapes Off-Label Use Claims For Heart Drug (Law360-$)
• “Compound King” Convicted in $21 Million Health Care Fraud Scheme (DOJ)
• Fired cancer scientist says ‘good people are being crushed’ by overzealous probes into possible Chinese ties (Science Mag)

• NICE, Health Technology Wales announce new partnership (PharmaTimes)
• UK MHRA: COVID-19 To Spark Rise In Clinical Trial-Related Deviations (Pink Sheet-$)
• UK Assesses Firms’ Coronavirus Resilience (Pink Sheet-$)
• European Commission approves Venclyxto plus Gazyvaro for adults with previously untreated chronic lymphocytic leukaemia (Press)
• Medicines: marketing authorisation holders submission of Nitrosamine risk evaluation (MHRA)

• Covid-19: India needs to get into vaccine production in a big way, says Kiran Mazumdar-Shaw (Economic Times)
• ICMR’s 30 influenza sites to test for Covid-19 cases (Economic Times)
• Covid-19: No near-term threat to pharma cos' credit profile (Economic Times)

• CF Canada pleads with Ottawa to pave way for access to life-saving drugs (CTVNews)

• Omega-3s Show No Overall Benefits for Heart Health or Cancer Prevention (NYTimes)